Bio-Path Holdings AI Stock Analysis
Want to see BPTH full AI Analyst Report?
Bio-Path Holdings (BPTH) AI Stock Analysis
Bio-Path Holdings
(Other OTC:BPTH)
BPTH scores near the bottom of the range. The dominant factor is a deeply distressed financial profile: no revenue, persistent losses, a shrinking asset base under $700,000, and negative stockholders' equity that raises serious going-concern and insolvency questions. Continued operations depend entirely on external financing that would likely be highly dilutive. Technicals reinforce the negative view, with the stock trading well below all key moving averages and negative MACD momentum; oversold RSI and Stochastic readings suggest only the possibility of short-term bounces, not a trend change. Valuation offers no support given negative earnings, no dividend, and a sub-$0.05 share price. This is an extremely high-risk, speculative situation.
Bio-Path Holdings (BPTH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $15.09K
- Dividend Yield
- ―
- Average Volume (3M)
- 97.00K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.54
- Revenue Growth
- ―
- EPS Growth
- 87.92%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bio-Path Holdings Business Overview & Revenue Model
Company Description
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbiliz...
How the Company Makes Money
As a clinical-stage biotechnology company, BPTH’s ability to generate recurring commercial revenue depends on successful development and eventual regulatory approval of its therapeutic candidates; however, specific, current revenue streams (e.g., pro...
Bio-Path Holdings Earnings Call Summary
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.
Bio-Path Holdings Financial Statement Overview
Summary
Financials are severely distressed. Bio-Path has generated zero revenue in every reported period and posted continuous losses, including an $8.7 million net loss in 2025. The balance sheet is the biggest concern: total assets have collapsed from $26.6 million in 2021 to roughly $678,000 in 2025, and stockholders' equity has turned negative at -$8.2 million, signaling book-value insolvency and material going-concern risk. Operating cash flow remains negative, and while the 2025 burn fell to -$1.6 million, this likely reflects a scaling back of clinical activity rather than genuine improvement. The company cannot self-fund and faces imminent, likely highly dilutive, capital-raising needs.
Income Statement
5Very NegativeBalance Sheet
3Very NegativeCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -34.00K | -96.00K | -159.00K | -178.00K | -178.00K | -161.00K |
| EBITDA | -2.09M | -8.24M | -9.73M | -15.66M | -13.69M | -10.28M |
| Net Income | -4.13M | -8.67M | -9.89M | -16.08M | -13.84M | -10.44M |
Balance Sheet | ||||||
| Total Assets | 6,000 | 678.00K | 3.88M | 3.22M | 15.97M | 26.57M |
| Cash, Cash Equivalents and Short-Term Investments | 2,000 | 0 | 1.17M | 1.05M | 10.38M | 23.77M |
| Total Debt | 520.00K | 463.00K | 83.00K | 113.00K | 221.00K | 235.00K |
| Total Liabilities | 9.69M | 8.90M | 3.73M | 2.78M | 1.80M | 1.11M |
| Stockholders Equity | -9.69M | -8.22M | 154.00K | 441.00K | 14.17M | 25.46M |
Cash Flow | ||||||
| Free Cash Flow | -77.00K | -1.60M | -10.57M | -11.54M | -15.12M | -9.99M |
| Operating Cash Flow | -77.00K | -1.60M | -10.57M | -11.54M | -15.10M | -9.92M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -21.00K | -70.00K |
| Financing Cash Flow | 79.00K | 423.00K | 10.70M | 2.20M | 1.73M | 20.01M |
Bio-Path Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Negative. The current price of 0.00 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 24.47 is Positive, neither overbought nor oversold. The STOCH value of 48.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTH.
Bio-Path Holdings Risk Analysis
Bio-Path Holdings disclosed 47 risk factors in its most recent earnings report. Bio-Path Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskBio-Path Holdings Peers Comparison
Overall Rating
CLRB46Neutral
MBRX44Neutral
CLDI41Neutral- BPTH39Underperform
MTNB38Underperform
NCNA33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CLRB | 46Neutral | $11.65M | -0.32 | -154.53% | ― | ― | 66.06% |
| MBRX | 44Neutral | $8.46M | -0.67 | -816.56% | ― | ― | 85.06% |
| CLDI | 41Neutral | $2.41M | -0.03 | -372.86% | ― | ― | 53.95% |
| BPTH | 39Underperform | $15.09K | -0.00 | 48.04% | ― | ― | 87.92% |
| MTNB | 38Underperform | $899.59K | -0.05 | -181.45% | ― | ― | 68.91% |
| NCNA | 33Underperform | $4.01M | -0.24 | -41.95% | ― | ― | 99.50% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BPTH | Bio-Path Holdings | 0.03 | -0.06 | -70.93% | |
| MTNB | Matinas BioPharma Holdings | 0.90 | -16.80 | -94.91% | |
| CLRB | Cellectar Biosciences Inc | 1.14 | -1.78 | -60.96% | |
| MBRX | Moleculin Biotech | 7.87 | -204.23 | -96.29% | |
| NCNA | Nucana Plc | 0.93 | -2.27 | -70.88% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.62 | -23.38 | -97.41% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026